Market Cap : 1.64 B | Enterprise Value : 1.76 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Myovant Sciences's annualized ROCE % for the quarter that ended in Jun. 2022 was -14.10%.
The historical data trend for Myovant Sciences's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2022 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | -186.962 | / | ( ( (725.027 - 281.34) | + | (520.011 - 250.33) ) | / 2 ) | |
= | -186.962 | / | ( (443.687 | + | 269.681) | / 2 ) | |
= | -186.962 | / | 356.684 | ||||
= | -52.42 % |
Myovant Sciences's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | -35.5 | / | ( ( (520.011 - 250.33) | + | (460.13 - 226.241) ) | / 2 ) | |
= | -35.5 | / | ( ( 269.681 | + | 233.889 ) | / 2 ) | |
= | -35.5 | / | 251.785 | ||||
= | -14.10 % |
(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Myovant Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Valente Nancy | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Mehra Uneek | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Merendino Lauren | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Marek David C | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Lo Andrew | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142 |
Viking Global Equities Master Ltd. | 10 percent owner | 55 RAILROAD AVENUE GREENWICH CT 06830 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
From GuruFocus
Other Sources
By Zacks 2020-12-16
By Zacks 2021-05-27
By Seekingalpha 2021-05-24
By Seekingalpha 2022-01-26
By Zacks 2021-03-25
By Fool 2021-07-28
By Zacks 2021-05-11
By Fool 2020-12-28
By Seekingalpha 2021-02-11
By Zacks 2020-12-29
By Seekingalpha 2021-06-02
By Zacks 2021-04-13